Personnel - Evotec CEO Lanthaler resigns prematurely
The pharmaceutical drug researcher Evotec has to look for a new boss. CEO Werner Lanthaler is stepping down before the end of his contract after almost 15 years for personal reasons, the MDax-listed company announced unexpectedly on Wednesday evening in Hamburg. The Supervisory Board had agreed to the resignation and was looking for a permanent successor both internally and externally. For the time being, Supervisory Board member Mario Polywka will manage the company. He had previously managed the day-to-day business at Evotec.
Lanthaler justified his resignation with an "extremely challenging and both physically and overall exhausting year 2023". He would "not be able to serve the company in the best possible way" in the coming years. Supervisory Board Chairwoman Iris Löw-Friedrich thanked the manager "for his unique vision and many important successes over the past almost 15 years". Lanthaler's contract would actually have run until March 2026.
Announcement
Read also:
- A clan member is punished here
- Traffic lawyer warns: Don't talk to the police!
- Will he be convicted as Jutta's murderer after 37 years?
- He also wanted to kill his cousin
- Despite Evotec being based in Hamburg, the German biotechnology company is listed on the MDAX, a segment of the Frankfurt Stock Exchange focused on medium-sized enterprises.
- Germany is known for its robust pharma industry, with Hamburg being a hub for various pharmaceutical companies, including Evotec, which specializes in drug discovery and development.
- Renowned personalities in the German pharma and biotechnology sectors have made significant contributions, with Werner Lanthaler, the former CEO of Evotec, being one of them.
Source: www.stern.de
